Banner: investors

News Releases

PURE Bioscience Appoints Vice President of Technology, Food Division

July 27, 2020

RANCHO CUCAMONGA, CA (July 27, 2020) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today announced the appointment of Jason Kawata as its new Vice President of Technology, Food Division.

Mr. Kawata is an accomplished food industry professional with over 20 years of experience.  For the past 17 years, Mr. Kawata served in progressively senior roles at Taylor Farms and was most recently Corporate Director of Quality Assurance and Technical Services. In this role, Mr. Kawata helped grow and support Taylor Farm’s restaurant, retail and national brands distribution network. Prior to joining Taylor Farms, Mr. Kawata held management positions at San Miguel Produce and Del Monte. 

“Having spent my career committed to protecting the United States food chain, I am keenly aware of the various challenges and the need for a safe and efficacious solution. PURE’s SDC-technology addresses that need by offering a farm-to-plate food safety solution that is truly unique in the industry. I’m excited to help grow the commercial adoption of PURE’s FDA and EPA registered solutions across the supply chain,” said Mr. Kawata.

“We are pleased to recruit a hands-on food safety professional with a proven track record to support the growth of PURE Bioscience. Mr. Kawata has the knowledge and experience required to enhance and expand PURE’s distribution and end-user customer network. He is well-known within the industry as a driver of enhanced food safety and we are proud to welcome him to our team,” said Tom Myers, PURE’s Chief Operating Officer.

About PURE Bioscience, Inc. 

PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena.  We provide solutions to combat the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain silver dihydrogen citrate, better known as SDC. This is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and mitigation of bacterial resistance. PURE is headquartered in Rancho Cucamonga, California (San Bernardino metropolitan area). Additional information on PURE is available at www.purebio.com

Forward-looking Statements:  Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; economic and other disruptions resulting from COVID-19; acceptance of the Company’s current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control and PURE Hard Surface into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to maintain relationships with its partners and other counterparties; the Company’s ability to generate sufficient revenues and reduce its operating expenses in order to reach profitability; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2019 and Form 10-Q for the third fiscal quarter ended April 30, 2020. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contact:        

Mark Elliott, VP Finance

PURE Bioscience, Inc.

Ph: 619-596-8600 ext: 116